Endonovo Therapeutics, Inc. Stock
Stocks
ENDV
US29272H3003
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
OTC Markets
11:14:59 2026-04-16 EDT
|
5-day change | 1st Jan Change | ||
| 0.000100 USD | -.--% |
|
-.--% | - |
| Market Cap | 2.77M 2.42M 2.28M 2.07M 3.88M 266M 3.9M 27.35M 10.55M 135M 10.42M 10.19M 435M | P/E 2021 |
-0.3x | P/E 2022 | -0.14x |
|---|---|---|---|---|---|
| Enterprise Value | 9.93M 8.66M 8.17M 7.42M 13.91M 952M 13.96M 97.9M 37.78M 484M 37.29M 36.46M 1.56B | EV / Sales 2021 |
112,421,804x | EV / Sales 2022 | 78,689,579x |
| Free-Float |
100% | Yield 2021 * |
-
| Yield 2022 | - |
| 6 months | +9,900.00% |
| 1 week | 0 | 0 | |
| 1 month | 0 | 0 | |
| Current year | 0 | 0 | |
| 1 year | 0 | 0 | |
| 3 years | 0 | 0.02 | |
| 5 years | 0 | 0.04 | |
| 10 years | 0 | 170 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 61 | 2012-02-29 |
Steven Barnes
IRC | Investor Relations Contact | - | 2014-04-30 |
Ira Weisberg
PRN | Corporate Officer/Principal | 77 | 2022-11-29 |
| Director | Title | Age | Since |
|---|---|---|---|
Alan Collier
CHM | Chairman | 61 | 2012-02-29 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/30/20 | Buy | Chief Executive Officer | 400 | 0.0045% | ||
| 2/21/20 | Buy | Chief Executive Officer | 100 | 0.0107% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | -.--% | -99.05% | 1.81K | ||
| -0.31% | +5.79% | +48.93% | +97.53% | 70.89B | ||
| +0.39% | +2.06% | +40.91% | +78.49% | 62.32B | ||
| -3.21% | -7.27% | -17.73% | +351.98% | 27.07B | ||
| +0.50% | +7.13% | +29.43% | +15.48% | 26.2B | ||
| -2.64% | -0.69% | -0.26% | -11.90% | 24.78B | ||
| +0.71% | +8.03% | +27.22% | -13.18% | 20.59B | ||
| -1.26% | -7.81% | +169.33% | +302.38% | 15.52B | ||
| -0.22% | +3.99% | +44.28% | +173.35% | 14.49B | ||
| +0.73% | +1.71% | -7.18% | +886.19% | 14.14B | ||
| Average | -0.53% | +1.59% | +33.49% | +178.13% | 27.6B | |
| Weighted average by Cap. | -0.49% | +1.49% | +36.35% | +148.21% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 0.07 0.06 0.06 0.05 0.1 7.01 0.1 0.72 0.28 3.57 0.27 0.27 11.48 | 0.14 0.12 0.11 0.1 0.19 12.99 0.19 1.33 0.52 6.6 0.51 0.5 21.25 |
| Net income | -3.1M -2.71M -2.56M -2.32M -4.35M -298M -4.37M -30.62M -11.82M -151M -11.66M -11.4M -487M | -18.47M -16.11M -15.21M -13.81M -25.88M -1.77B -25.99M -182M -70.32M -901M -69.4M -67.86M -2.9B |
| Net Debt | 7.1M 6.19M 5.84M 5.3M 9.94M 681M 9.98M 69.98M 27M 346M 26.65M 26.06M 1.11B | 7.15M 6.24M 5.89M 5.35M 10.02M 686M 10.06M 70.55M 27.22M 349M 26.87M 26.27M 1.12B |
Employees
1
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-17 | US$0.000001 | -99.00% | 5,000 |
| 26-09-16 | US$0.000100 | -.--% | 40,000 |
| 26-09-14 | US$0.000100 | -.--% | 270,000 |
| 26-09-10 | US$0.000100 | -.--% | 1,000,000 |
- Stock Market
- Stocks
- ENDV Stock
Select your edition
All financial news and data tailored to specific country editions
















